Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)
Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.
Aim(s): We aimed to understand real‐world management and treatment of gastroenteropancreatic (GEP) NETs.
Materials and methods: A retrospective analysis was performed for metastatic GEP‐NETs patients treated with SSAs at the medical oncology department of the academic hospital of Oran between January 1, 2011 and December 31, 2018. We reported descriptive statistics, clinical characteristics, treatment patterns, and healthcare resource use.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.